1c2i › Citations

Design of potent selective zinc-mediated serine protease inhibitors.

Katz BA, Clark JM, Finer-Moore JS, Jenkins TE, Johnson CR, Ross MJ, Luong C, Moore WR, Stroud RM
Nature 391 608-12 (1998)
Related entries: 1c1n, 1c1o, 1c1p, 1c1q, 1c1r, 1c1t, 1c1u, 1c1v, 1c1w, 1c2d, 1c2e, 1c2f, 1c2g, 1c2h, 1c2j, 1c2k, 1c2l, 1c2m, 1xuf, 1xug, 1xuh, 1xui, 1xuj, 1xuk

Cited: 75 times
EuropePMC logo PMID: 9468142

Abstract

Many serine proteases are targets for therapeutic intervention because they often play key roles in disease. Small molecule inhibitors of serine proteases with high affinity are especially interesting as they could be used as scaffolds from which to develop drugs selective for protease targets. One such inhibitor is bis(5-amidino-2-benzimidazolyl)methane (BABIM), standing out as the best inhibitor of trypsin (by a factor of over 100) in a series of over 60 relatively closely related analogues. By probing the structural basis of inhibition, we discovered, using crystallographic methods, a new mode of high-affinity binding in which a Zn2+ ion is tetrahedrally coordinated between two chelating nitrogens of BABIM and two active site residues, His57 and Ser 195. Zn2+, at subphysiological levels, enhances inhibition by over 10(3)-fold. The distinct Zn2+ coordination geometry implies a strong dependence of affinity on substituents. This unique structural paradigm has enabled development of potent, highly selective, Zn2+-dependent inhibitors of several therapeutically important serine proteases, using a physiologically ubiquitous metal ion.

Reviews citing this publication (8)

  1. An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy. Pillaiyar T, Manickam M, Namasivayam V, Hayashi Y, Jung SH. J Med Chem 59 6595-6628 (2016)
  2. Mast cell tryptases and chymases in inflammation and host defense. Caughey GH. Immunol Rev 217 141-154 (2007)
  3. Orthogonal multipolar interactions in structural chemistry and biology. Paulini R, Müller K, Diederich F. Angew Chem Int Ed Engl 44 1788-1805 (2005)
  4. Biology of mast cell tryptase. An inflammatory mediator. Hallgren J, Pejler G. FEBS J 273 1871-1895 (2006)
  5. The emergence of life on Earth. Lahav N, Nir S, Elitzur AC. Prog Biophys Mol Biol 75 75-120 (2001)
  6. Tryptase inhibitors: a patent review. Ni WW, Cao MD, Huang W, Meng L, Wei JF. Expert Opin Ther Pat 27 919-928 (2017)
  7. Bioinorganic chemistry and drug design: here comes zinc again. Thorp HH. Chem Biol 5 R125-7 (1998)
  8. Current trends in quantitative structure activity relationships on FXa inhibitors: evaluation and comparative analysis. Kontogiorgis CA, Hadjipavlou-Litina D. Med Res Rev 24 687-747 (2004)

Articles citing this publication (67)

  1. The maximal affinity of ligands. Kuntz ID, Chen K, Sharp KA, Kollman PA. Proc Natl Acad Sci U S A 96 9997-10002 (1999)
  2. Polder maps: improving OMIT maps by excluding bulk solvent. Liebschner D, Afonine PV, Moriarty NW, Poon BK, Sobolev OV, Terwilliger TC, Adams PD. Acta Crystallogr D Struct Biol 73 148-157 (2017)
  3. 5-Carboxy-8-hydroxyquinoline is a Broad Spectrum 2-Oxoglutarate Oxygenase Inhibitor which Causes Iron Translocation. Hopkinson RJ, Tumber A, Yapp C, Chowdhury R, Aik W, Che KH, Li XS, Kristensen JBL, King ONF, Chan MC, Yeoh KK, Choi H, Walport LJ, Thinnes CC, Bush JT, Lejeune C, Rydzik AM, Rose NR, Bagg EA, McDonough MA, Krojer T, Yue WW, Ng SS, Olsen L, Brennan PE, Oppermann U, Muller-Knapp S, Klose RJ, Ratcliffe PJ, Schofield CJ, Kawamura A. Chem Sci 4 3110-3117 (2013)
  4. Towards an integrated description of hydrogen bonding and dehydration: decreasing false positives in virtual screening with the HYDE scoring function. Reulecke I, Lange G, Albrecht J, Klein R, Rarey M. ChemMedChem 3 885-897 (2008)
  5. Conversion of agonist site to metal-ion chelator site in the beta(2)-adrenergic receptor. Elling CE, Thirstrup K, Holst B, Schwartz TW. Proc Natl Acad Sci U S A 96 12322-12327 (1999)
  6. Biochemical characterization of prostasin, a channel activating protease. Shipway A, Danahay H, Williams JA, Tully DC, Backes BJ, Harris JL. Biochem Biophys Res Commun 324 953-963 (2004)
  7. Crystal structure of a prostate kallikrein isolated from stallion seminal plasma: a homologue of human PSA. Carvalho AL, Sanz L, Barettino D, Romero A, Calvete JJ, Romão MJ. J Mol Biol 322 325-337 (2002)
  8. Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors. Boldt GE, Kennedy JP, Hixon MS, McAllister LA, Barbieri JT, Tzipori S, Janda KD. J Comb Chem 8 513-521 (2006)
  9. The structure of the human betaII-tryptase tetramer: fo(u)r better or worse. Sommerhoff CP, Bode W, Pereira PJ, Stubbs MT, Stürzebecher J, Piechottka GP, Matschiner G, Bergner A. Proc Natl Acad Sci U S A 96 10984-10991 (1999)
  10. Exoplasmic cysteine Cys384 of the HDL receptor SR-BI is critical for its sensitivity to a small-molecule inhibitor and normal lipid transport activity. Yu M, Romer KA, Nieland TJ, Xu S, Saenz-Vash V, Penman M, Yesilaltay A, Carr SA, Krieger M. Proc Natl Acad Sci U S A 108 12243-12248 (2011)
  11. A comparison of the pharmacophore identification programs: Catalyst, DISCO and GASP. Patel Y, Gillet VJ, Bravi G, Leach AR. J Comput Aided Mol Des 16 653-681 (2002)
  12. Inhibition of allergen-induced pulmonary responses by the selective tryptase inhibitor 1,5-bis-[4-[(3-carbamimidoyl-benzenesulfonylamino)-methyl]-phenoxy]-pen tane (AMG-126737). Wright CD, Havill AM, Middleton SC, Kashem MA, Dripps DJ, Abraham WM, Thomson DS, Burgess LE. Biochem Pharmacol 58 1989-1996 (1999)
  13. Inhibitory zinc sites in enzymes. Maret W. Biometals 26 197-204 (2013)
  14. Trypsin specificity as elucidated by LIE calculations, X-ray structures, and association constant measurements. Leiros HK, Brandsdal BO, Andersen OA, Os V, Leiros I, Helland R, Otlewski J, Willassen NP, Smalås AO. Protein Sci 13 1056-1070 (2004)
  15. Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum neurotoxin serotype A. Park JG, Sill PC, Makiyi EF, Garcia-Sosa AT, Millard CB, Schmidt JJ, Pang YP. Bioorg Med Chem 14 395-408 (2006)
  16. Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity. Wu P, Leinonen J, Koivunen E, Lankinen H, Stenman UH. Eur J Biochem 267 6212-6220 (2000)
  17. Metal impurities cause false positives in high-throughput screening campaigns. Hermann JC, Chen Y, Wartchow C, Menke J, Gao L, Gleason SK, Haynes NE, Scott N, Petersen A, Gabriel S, Vu B, George KM, Narayanan A, Li SH, Qian H, Beatini N, Niu L, Gan QF. ACS Med Chem Lett 4 197-200 (2013)
  18. Structural basis of mercury- and zinc-conjugated complexes as SARS-CoV 3C-like protease inhibitors. Lee CC, Kuo CJ, Hsu MF, Liang PH, Fang JM, Shie JJ, Wang AH. FEBS Lett 581 5454-5458 (2007)
  19. Using an Enzyme's Active Site To Template Inhibitors This work was supported by the Centre National de la Recherche Scientifique and by the Ecole Polytechnique (predoctoral fellowship to R.N.). We thank Prof. Jean-Marie Lehn for stimulating discussions. Nguyen R, Huc I. Angew Chem Int Ed Engl 40 1774-1776 (2001)
  20. Crystal structure of recombinant human tissue kallikrein at 2.0 A resolution. Katz BA, Liu B, Barnes M, Springman EB. Protein Sci 7 875-885 (1998)
  21. Metal ions as cofactors for the binding of inhibitors to methionine aminopeptidase: a critical view of the relevance of in vitro metalloenzyme assays. Schiffmann R, Heine A, Klebe G, Klein CD. Angew Chem Int Ed Engl 44 3620-3623 (2005)
  22. Noncovalent modification of chymotrypsin surface using an amphiphilic polymer scaffold: implications in modulating protein function. Sandanaraj BS, Vutukuri DR, Simard JM, Klaikherd A, Hong R, Rotello VM, Thayumanavan S. J Am Chem Soc 127 10693-10698 (2005)
  23. Selective inhibition of beta-1,4- and alpha-1,3-galactosyltransferases: donor sugar-nucleotide based approach. Takayama S, Chung SJ, Igarashi Y, Ichikawa Y, Sepp A, Lechler RI, Wu J, Hayashi T, Siuzdak G, Wong CH. Bioorg Med Chem 7 401-409 (1999)
  24. Respiratory syncytial virus: recent progress towards the discovery of effective prophylactic and therapeutic agents. Meanwell NA, Krystal M. Drug Discov Today 5 241-252 (2000)
  25. Crystal Structure of Feline Infectious Peritonitis Virus Main Protease in Complex with Synergetic Dual Inhibitors. Wang F, Chen C, Liu X, Yang K, Xu X, Yang H. J Virol 90 1910-1917 (2016)
  26. Prediction of Ordered Water Molecules in Protein Binding Sites from Molecular Dynamics Simulations: The Impact of Ligand Binding on Hydration Networks. Rudling A, Orro A, Carlsson J. J Chem Inf Model 58 350-361 (2018)
  27. X-ray crystallographic analyses of complexes between bovine beta-trypsin and Schiff base copper(II) or iron(III) chelates. Toyota E, Ng KK, Sekizaki H, Itoh K, Tanizawa K, James MN. J Mol Biol 305 471-479 (2001)
  28. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA). Katz BA, Luong C, Ho JD, Somoza JR, Gjerstad E, Tang J, Williams SR, Verner E, Mackman RL, Young WB, Sprengeler PA, Chan H, Mortara K, Janc JW, McGrath ME. J Mol Biol 344 527-547 (2004)
  29. Modulation of zinc toxicity by tissue plasminogen activator. Siddiq MM, Tsirka SE. Mol Cell Neurosci 25 162-171 (2004)
  30. Metal mediated inhibition of methionine aminopeptidase by quinolinyl sulfonamides. Huang M, Xie SX, Ma ZQ, Hanzlik RP, Ye QZ. Biochem Biophys Res Commun 339 506-513 (2006)
  31. Recruiting Zn2+ to mediate potent, specific inhibition of serine proteases. Katz BA, Luong C. J Mol Biol 292 669-684 (1999)
  32. Structure-activity relationship studies of a bisbenzimidazole-based, Zn(2+)-dependent inhibitor of HCV NS3 serine protease. Yeung KS, Meanwell NA, Qiu Z, Hernandez D, Zhang S, McPhee F, Weinheimer S, Clark JM, Janc JW. Bioorg Med Chem Lett 11 2355-2359 (2001)
  33. Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits. Abendschein DR, Baum PK, Martin DJ, Vergona R, Post J, Rumennik G, Sullivan ME, Eisenberg PR, Light DR. J Cardiovasc Pharmacol 35 796-805 (2000)
  34. Highly potent non-peptidic inhibitors of the HCV NS3/NS4A serine protease. Sperandio D, Gangloff AR, Litvak J, Goldsmith R, Hataye JM, Wang VR, Shelton EJ, Elrod K, Janc JW, Clark JM, Rice K, Weinheimer S, Yeung KS, Meanwell NA, Hernandez D, Staab AJ, Venables BL, Spencer JR. Bioorg Med Chem Lett 12 3129-3133 (2002)
  35. A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering. Sananes A, Cohen I, Shahar A, Hockla A, De Vita E, Miller AK, Radisky ES, Papo N. J Biol Chem 293 12663-12680 (2018)
  36. The salt-sensitive structure and zinc inhibition of Borrelia burgdorferi protease BbHtrA. Russell TM, Tang X, Goldstein JM, Bagarozzi D, Johnson BJ. Mol Microbiol 99 586-596 (2016)
  37. Dual-action inhibitors of HIF prolyl hydroxylases that induce binding of a second iron ion. Yeoh KK, Chan MC, Thalhammer A, Demetriades M, Chowdhury R, Tian YM, Stolze I, McNeill LA, Lee MK, Woon ECY, Mackeen MM, Kawamura A, Ratcliffe PJ, Mecinović J, Schofield CJ. Org Biomol Chem 11 732-745 (2013)
  38. Inhibition of arginine gingipains (RgpB and HRgpA) with benzamidine inhibitors: zinc increases inhibitory potency. Krauser JA, Potempa J, Travis J, Powers JC. Biol Chem 383 1193-1198 (2002)
  39. Understanding binding selectivity toward trypsin and factor Xa: the role of aromatic interactions. Di Fenza A, Heine A, Koert U, Klebe G. ChemMedChem 2 297-308 (2007)
  40. Divergent Inhibitor Susceptibility among Airway Lumen-Accessible Tryptic Proteases. Nimishakavi S, Raymond WW, Gruenert DC, Caughey GH. PLoS One 10 e0141169 (2015)
  41. Hybrid organic-inorganic inhibitors of a PDZ interaction that regulates the endocytic fate of CFTR. Kundu R, Cushing PR, Popp BV, Zhao Y, Madden DR, Ball ZT. Angew Chem Int Ed Engl 51 7217-7220 (2012)
  42. Metal-mediated inhibition is a viable approach for inhibiting cellular methionine aminopeptidase. Chai SC, Ye QZ. Bioorg Med Chem Lett 19 6862-6864 (2009)
  43. Novel amidino-substituted benzimidazoles: synthesis of compounds and inhibition of dipeptidyl peptidase III. Agić D, Hranjec M, Jajcanin N, Starcević K, Karminski-Zamola G, Abramić M. Bioorg Chem 35 153-169 (2007)
  44. Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity. Wang XA, Cianci CW, Yu KL, Combrink KD, Thuring JW, Zhang Y, Civiello RL, Kadow KF, Roach J, Li Z, Langley DR, Krystal M, Meanwell NA. Bioorg Med Chem Lett 17 4592-4598 (2007)
  45. A novel FRET peptide assay reveals efficient Helicobacter pylori HtrA inhibition through zinc and copper binding. Bernegger S, Brunner C, Vizovišek M, Fonovic M, Cuciniello G, Giordano F, Stanojlovic V, Jarzab M, Simister P, Feller SM, Obermeyer G, Posselt G, Turk B, Cabrele C, Schneider G, Wessler S. Sci Rep 10 10563 (2020)
  46. High molecular weight kininogen as substrate for cathepsin B. Barros NM, Tersariol IL, Oliva ML, Araújo MS, Sampaio CA, Juliano L, Motta G. Biol Chem 385 551-555 (2004)
  47. Synthesis of some benzimidazole derivatives endowed with 1,2,3-triazole as potential inhibitors of hepatitis C virus. Youssif BG, Mohamed YA, Salim MT, Inagaki F, Mukai C, Abdu-Allah HH. Acta Pharm 66 219-231 (2016)
  48. Metal mediated protease inhibition: design and synthesis of inhibitors of the human cytomegalovirus (hCMV) protease. Dhanak D, Burton G, Christmann LT, Darcy MG, Elrod KC, Kaura A, Keenan RM, Link JO, Peishoff CE, Shah DH. Bioorg Med Chem Lett 10 2279-2282 (2000)
  49. Synthesis and evaluation of guanidine-containing Schiff base copper(II), zinc(II), and iron(III) chelates as trypsin inhibitors. Toyota E, Sekizaki H, Itoh K, Tanizawa K. Chem Pharm Bull (Tokyo) 51 625-629 (2003)
  50. Associative Interactions among Zinc, Apolipoprotein E, and Amyloid-β in the Amyloid Pathology. Oh SB, Kim JA, Park S, Lee JY. Int J Mol Sci 21 E802 (2020)
  51. Allosteric Regulation of an HIV-1 Protease Inhibitor by Zn(II) Ions This work was funded by MURST (COFIN2000-MM03194891). We thank Prof. P. Tecilla (U. Trieste) for valuable comments. Valente S, Gobbo M, Licini G, Scarso A, Scrimin P. Angew Chem Int Ed Engl 40 3899-3902 (2001)
  52. Amides of xanthurenic acid as zinc-dependent inhibitors of Lp-PLA(2). Lin EC, Hu Y, Amantea CM, Pham LM, Cajica J, Okerberg E, Brown HE, Fraser A, Du L, Kohno Y, Ishiyama J, Kozarich JW, Shreder KR. Bioorg Med Chem Lett 22 868-871 (2012)
  53. Enhancement of the binding affinity of methylene blue to site I in human serum albumin by cupric and ferric ions. He LL, Wang YX, Wu XX, Liu XP, Wang X, Liu B, Wang X. Luminescence 30 1380-1388 (2015)
  54. Expression and characterization of recombinant mast cell tryptase. Chan H, Elrod KC, Numerof RP, Sideris S, Clark JM. Protein Expr Purif 15 251-257 (1999)
  55. Novel, potent, selective, and orally bioavailable human betaII-tryptase inhibitors. Sperandio D, Tai VW, Lohman J, Hirschbein B, Mendonca R, Lee CS, Spencer JR, Janc J, Nguyen M, Beltman J, Sprengeler P, Scheerens H, Lin T, Liu L, Gadre A, Kellogg A, Green MJ, McGrath ME. Bioorg Med Chem Lett 16 4085-4089 (2006)
  56. Synthesis of new (benzimidazolyl)piperazines with affinity for the 5-HT1A receptor via Pd(0) amination of bromobenzimidazoles. López-Rodríguez ML, Viso A, Benhamú B, Rominguera JL, Murcia M. Bioorg Med Chem Lett 9 2339-2342 (1999)
  57. Amides of 4-hydroxy-8-methanesulfonylamino-quinoline-2-carboxylic acid as zinc-dependent inhibitors of Lp-PLA₂. Hu Y, Lin EC, Pham LM, Cajica J, Amantea CM, Okerberg E, Brown HE, Fraser A, Du L, Kohno Y, Ishiyama J, Kozarich JW, Shreder KR. Bioorg Med Chem Lett 23 1553-1556 (2013)
  58. Inhibition of alpha-chymotrypsin with thiol-bearing substrate analogues in the presence of zinc ion. Han MS, Oh DJ, Kim DH. Bioorg Med Chem Lett 14 701-705 (2004)
  59. Natural anionic polymer acts as highly efficient trypsin inhibitor based on an electrostatic interaction mechanism. Lv Y, Zhang J, Song Y, Wang B, Wang S, Zhao S, Lv G, Ma X. Macromol Rapid Commun 35 1606-1610 (2014)
  60. Synergistic inhibition of carboxypeptidase A by zinc ion and imidazole. Mock WL, Wang L. Biochem Biophys Res Commun 257 239-243 (1999)
  61. Thiophilic-interaction chromatography of enzymatically active tissue prostate-specific antigen (T-PSA) and its modulation by zinc ions. Satheesh Babu AK, Vijayalakshmi MA, Smith GJ, Chadha KC. J Chromatogr B Analyt Technol Biomed Life Sci 861 227-235 (2008)
  62. Zinc(II)-mediated inhibition of a ribonuclease by an N-hydroxyurea nucleotide. Higgin JJ, Yakovlev GI, Mitkevich VA, Makarov AA, Raines RT. Bioorg Med Chem Lett 13 409-412 (2003)
  63. Extraction, purification, and biochemical characterization of serine protease from leaves of Abrus precatorius. Serge NE, Laurette Blandine MK, Kumar S, Clergé T, Vijayalakshmi M. Prep Biochem Biotechnol 47 1016-1024 (2017)
  64. Generation of potent coagulation protease inhibitors utilizing zinc-mediated chelation. Young WB, Sprengeler P, Shrader WD, Li Y, Rai R, Verner E, Jenkins T, Fatheree P, Kolesnikov A, Janc JW, Cregar L, Elrod K, Katz B. Bioorg Med Chem Lett 16 710-713 (2006)
  65. Monocharged inhibitors of mast cell tryptase derived from potent and selective dibasic inhibitors. Dener JM, Wang VR, Rice KD, Gangloff AR, Kuo EY, Newcomb WS, Putnam D, Wong M. Bioorg Med Chem Lett 11 2325-2330 (2001)
  66. Synthesis, molecular modeling, and biological evaluation of novel benzimidazole derivatives as inhibitors of hepatitis C virus RNA replication. El Diwani HI, Abdel-Mohsen HT, Salama I, Ragab FA, Ramla MM, Galal SA, Abdalla MM, Abdel-Wahab A, El Demellawy MA. Chem Pharm Bull (Tokyo) 62 856-866 (2014)
  67. Identification of metabolites of the tryptase inhibitor CRA-9249: observation of a metabolite derived from an unexpected hydroxylation pathway. Yu W, Dener JM, Dickman DA, Grothaus P, Ling Y, Liu L, Havel C, Malesky K, Mahajan T, O'Brian C, Shelton EJ, Sperandio D, Tong Z, Yee R, Mordenti JJ. Bioorg Med Chem Lett 16 4053-4058 (2006)


Quick links